PainReform (NASDAQ:PRFX) and Corcept Therapeutics (NASDAQ:CORT) Head to Head Comparison

PainReform (NASDAQ:PRFX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Volatility & Risk

PainReform has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Profitability

This table compares PainReform and Corcept Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Corcept Therapeutics	16.53%	22.56%	17.83%

Institutional and Insider Ownership

37.3% of PainReform shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PainReform and Corcept Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Corcept Therapeutics	1	2	5	0	2.50

Corcept Therapeutics has a consensus price target of $139.50, suggesting a potential upside of 91.70%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than PainReform.

Valuation and Earnings

This table compares PainReform and Corcept Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$31,000.00	24.41	-$5.02 million	($736.66)	-0.00
Corcept Therapeutics	$761.41 million	10.46	$99.65 million	$1.27	57.30

Corcept Therapeutics has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Corcept Therapeutics beats PainReform on 11 of the 14 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.